A finite supply of donor organs has led many transplant centers to accept marginal liver allografts with increasing frequency. These allografts may be at higher risk of primary nonfunction, early allograft dysfunction, and other recipient complications following liver transplantation. Machine perfusion preservation is an emerging technology that limits ischemia/reperfusion injury associated with preservation and may lead to improved outcomes following transplantation. Increased used of machine perfusion in liver preservation may permit an expansion of the donor pool. In this review, we examine the major clinical experience of hypothermic machine perfusion in human liver transplantation.
Introduction
The number of patients on the liver transplant waiting list far exceeds the number who make it to the operating room for liver transplantation. In 2016, 7,841 patients received a liver transplant in the United States, while 12,733 more patients were added to the already extensive list. (1) With increasing demand, centers are turning to marginal liver allografts from extended criteria donors (ECDs) and donation after cardiac death (DCD). (2, 3) Due to their susceptibility to ischemia/ reperfusion injury, use of these marginal donor allografts has significant consequences, including increased rates of primary nonfunction, early graft dysfunction, biliary complications, decreased longterm graft survival, and increased hospital resource use after transplantation. (4) (5) (6) (7) Despite the increased use of more marginal allografts, many potentially viable grafts are declined, opening the door for improving organ preservation through machine perfusion preservation to safely broaden the use of marginal allografts. (8) (9) (10) (11) As the transplant community continues to push the boundaries, including allografts traditionally considered "unfit" for transplantation, it is essential that organ preservation techniques are optimized, allowing for the best possible chance of sustained allograft resuscitation during organ preservation. Hypothermic machine perfusion (HMP) is an emerging technology that limits the ischemia/reperfusion injury sustained during allograft preservation and potentially leads to improved outcomes following liver transplantation.
Early Developments in HMP in Liver Transplantation
Static cold storage (SCS) techniques have been the mainstay of liver allograft preservation since the inception of liver transplantation and continue to be the standard method for liver preservation. In 1967, Brettschneider et al. (12) described the first use of machine perfusion for the preservation of liver allografts in an animal model. However, machine perfusion gained very little traction in the research and clinical arenas due to the simplicity of cold storage with the introduction of University of Wisconsin solution in the 1980s. Over the last 2 decades, several studies in rodent models have demonstrated the potential for improvement in outcomes using HMP techniques. (13) (14) (15) (16) (17) (18) (19) As the demand for donor organs exceeded the supply, clinical experience with machine perfusion for organ preservation proved promising, particularly with marginal allografts. Several large randomized clinical trials comparing HMP and SCS in cadaveric and DCD donors in kidney transplantation demonstrated improved graft and patient outcomes, giving rise to the initial interest and acceptance of this preservation technique. (20, 21) In 2009, results of the first human trial using machine perfusion in liver allografts were reported. Following the initial success and recognition of the potential of this modality, there has been a growing interest and widespread implementation of HMP. Additionally, several benefits have been demonstrated in animal and human discard models of machine perfusion in liver transplantation. These include the preservation of donor allografts, providing nutrients and oxygen at various temperatures, and optimization of donor organ function during the perfusion/cold storage period. (22) Although the clinical application of machine perfusion remains investigational in liver transplantation, its utility and efficacy in organ preservation of standard criteria donor (SCD), ECD, and DCD allografts have been demonstrated by the growing number of clinical trials and rapid implementation in the clinical setting.
Clinical Experience of HMP in Human Liver Transplantation
A summary of the reported human clinical experience involving the use of HMP in liver transplantation is presented in Table 1 . Representative examples of the three primary HMP systems used in liver transplantation are shown in Fig. 1 . The first prospective casecontrolled liver HMP trial was reported by Guarrera et al. in 2009 . (23) Twenty adult liver allografts underwent HMP and were compared with a matched group of SCS liver allografts. This initial trial demonstrated significantly lower serum injury markers and mean hospital length of stay in the HMP group; there were fewer biliary complications in the HMP livers, with comparable early allograft dysfunction rates. (23) Ischemia/reperfusion injury may have been mitigated by a reduction in proinflammatory cytokine expression relieving downstream activation of adhesion molecules and migration of neutrophils and macrophages relative to SCS controls. (24) This initial trial demonstrated the safety and feasibility of HMP techniques.
Several trials were then focused on using HMP with marginal allografts and high-risk organs for transplantation. Dutkowski et al. (25) assessed outcomes in 8 patients receiving DCD allografts and HMP. Median donor warm ischemia time was 38 minutes followed by standard SCS techniques and hypothermic oxygenated perfusion for 1-2 hours prior to implantation. No evidence of intrahepatic biliary or other allograft dysfunction following machine perfusion was found. Further, they reported comparable or better results in the HMP group with hospital and intensive care unit length of stay, kidney function, and markers of preservation injury, with a median follow-up time of 8.5 months. They concluded that machine perfusion is a well-tolerated modality that is promising in the protection of early and late allograft injury in DCD donors. (25) Guarrera et al. (26) subsequently used ECD livers initially declined by the originating United Network for Organ Sharing region to further assess the benefit and utility of HMP in marginal allografts. Thirty-one ECD-HMP allografts in a matched cohort study design were compared with ECD-SCS liver allografts. One-year patient survival and early allograft dysfunction rates were similar between the groups. Post-hoc analysis revealed significantly fewer biliary complications and hospital length of stay in those receiving HMP. (26) Given the increased risk of intrahepatic ischemic cholangiopathy and potential for graft loss with increased warm ischemia time, Dutkowski et al. (27) published a multicenter trial evaluating hypothermic oxygenated perfusion techniques in DCD liver allografts. This study evaluated 25 DCD livers treated with HMP that were matched and compared with SCS-DCD liver grafts (n 5 50). The HMP and SCS-DCD livers were then compared with liver allografts from SCS-donor after brain death allografts (n 5 50). They found significantly reduced early allograft dysfunction (as shown by peak alanine aminotransferase [ALT] and rate of ischemic cholangiopathy) in the HMP-DCD livers compared with the SCS-DCD livers. Additionally, there was a significant reduction in the rate of biliary complications and improved 1-year graft survival in the HMP-DCD group compared with the SCS-DCD group. When comparing HMP-DCD and SCS-donor after brain death groups, both achieved similar results in the above investigated end points. (27) This suggests that HMP may improve graft quality before implantation, making DCD allografts "behave" more like low-risk allografts.
Further evaluation of DCD allografts with HMP has been undertaken by Porte's group from Groningen, the Netherlands. (28) A prospective case-control study was designed. In this study, 10 DCD livers treated with dual hypothermic oxygenated machine perfusion (DHOPE) were compared with 20 control DCD-SCS livers. Consistent with prior HMP-treated DCD results, DHOPE was shown to be protective in DCD liver grafts and have the potential for restoration of hepatocellular energy status; hepatic adenosine triphosphate content increased 11-fold and reperfusion injury was reduced, as peak ALT and bilirubin levels were 2-fold lower in the DHOPE group. Six-month graft survival and 1-year graft and patient survival rates were 100% in the DHOPE group compared with 80%, 67%, and 85%, respectively, in the control group. (28) There currently are no clinical trials evaluating a combination of normothermic machine perfusion and HMP; however, De Carlis et al. (29) described a unique experience using both modalities in clinical practice with a case study in a 47-year-old donor arriving in cardiac arrest followed by allograft procurement. The decision to use both modalities was due to the protracted warm ischemia time of 135 minutes. Normothermic regional perfusion lasting 8 hours following the warm ischemia period allowed for liver assessment with hourly blood gas analyses as well as liver and kidney function tests. A SCS time of 4 hours was implemented for retrieval, organ delivery, and back-table preparation, followed by 3 hours of HMP. The study reported no complications, no biliary complications, and normal liver function in the early postoperative period. (29) Viability Assessment of the Marginal Liver Allograft With HMP Normothermic machine perfusion allows for the assessment of allograft viability during perfusion vis-avis bile production, biliary chemistry, and changes in lactic acid levels. (30) While these changes may not be observed in HMP, several markers can be evaluated in the metabolically quiescent HMP allograft, permitting some degree of viability and quality assessment. Aspartate aminotransferase (AST), ALT, and lactate (27) dehydrogenase are primarily cytoplasmic enzymes and are used as markers of hepatocyte injury that are present in the effluent perfusate. In the first clinical trial of HMP, peak recipient AST correlated with 2-hour effluent AST, ALT, and lactate dehydrogenase, suggesting an on-the-go viability testing of effluent chemistry biomarkers could be used in conjugation with donor history, hands-on assessment, and biopsy data. (23) HMP has evolved into the preferred method of ECD kidney preservation and is used extensively in DCD renal transplantation, with perfusion parameters, such as flow and resistance, being used to evaluate donor kidneys. (21, (31) (32) (33) (34) In animal preservation models of liver allografts, increasing warm ischemia time has been correlated with increased hepatic arterial resistance. Additionally, allografts with lower warm ischemia time are reported to have decreased normalized hepatic artery (HA) pump pressures and subsequently lower hepatocellular enzyme release at transplantation. (35, 36) Lower portal venous pressure and resistance during perfusion are early discriminators of early graft viability. (37) These studies suggest that, much like kidney transplantation, portal vein (PV) and HA perfusion pressures and resistances may be predictive of allograft viability and subsequent function.
While the safety and efficacy of HMP in liver transplantation have been demonstrated, the extent and criteria governing its use and distinguishing between transplantable and nontransplantable allografts have yet to be fully established. As we continue to use ECD and DCD donors with increasing success, it is essential that we continue to develop parameters to assess these marginal donors during the preservation period, identifying the factors that are responsible for the ongoing successes of HMP in liver transplantation. 
Conclusion and the Future of Machine Preservation in Liver Transplantation
The potential donor pool is increasingly characterized by donors of older age, higher body mass index, and increasing comorbidities. These factors may have a profound impact on the pool of available liver allografts in the future. HMP reduces the preservation injury of these marginal allografts, thus leading to a reduction in early allograft dysfunction. Continued use of the same traditional cold storage preservation techniques may result in many marginal organs remaining as discards. Further development of machine preservation techniques, including both normothermic and hypothermic, may allow for the best use of the future allograft pool. As the discussion on organ allocation policy changes continues, if implemented, redistricting could increase average cold ischemia time. The negative effects of increased cold ischemia time could be ameliorated through the use of machine perfusion technology. Recently in Italy, HMP was used to safely extend the cold ischemia time up to 20 hours in two cases of necessity, with a normal postoperative course and uncomplicated follow-up at 4 and 9 months. (38) If HMP allows safe preservation into the 24-hour time range, nearly all logistic obstacles may be overcome.
Current multicenter trials are underway to evaluate the use of portable HMP devices. This would enable SCD, DCD, and ECD allografts to have the benefit of reduction of preservation injury while in transit. Furthermore, implementation of an innovative and portable HMP system with cannulation of the liver graft in the donor operating room will enable us to better understand the full benefits of this novel preservation technique. This would limit the time with standard cold storage and maximize the hypothermic perfusion duration. Other novel techniques using normothermic perfusion have shown promising results as an ex vivo perfusion technique as well. Normothermic perfusion has the benefit of improved assessment of organ viability during perfusion; however, use as a portable technique is somewhat risky in that any failure of the device could result in a catastrophic loss of the organ due to the inability to cool the organ in a sterile environment. Conversely, with HMP, device failure would simply revert to an environment analogous to SCS.
While the precise manner in which ex vivo liver perfusion will be broadly implemented is unclear, recent evidence confirms that cold storage techniques are inferior to HMP and place DCD and other marginal liver allografts at an increased risk of preservation injury as well as short-term and longterm complications to the recipient. The continued development and refinement of ex vivo liver machine perfusion techniques are essential to increase the use of liver allografts, which in turn will help close the gap between organ supply and demand and improve patient outcomes.
